Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
mTOR inhibitor immunosuppressant

Rapamune (sirolimus)

An approved treatment for Lymphangioleiomyomatosis.

FDA Approved (2015)by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2015

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Sirolimus wherever you encounter it, plus the key facts at a glance.

Generic name
Sirolimus
Brand name
Rapamune
Drug class
mTOR inhibitor immunosuppressant
Manufacturer
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
How it's taken
Oral tablet or oral solution, once a day

A once-daily pill or oral solution, taken by mouth, that is FDA approved for lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women[13].

  • The FDA approved the LAM use on May 28, 2015[4].
  • Rapamune was first approved in 1999 to help prevent rejection after a kidney transplant, and that is still its other labeled use, for people 13 and older[5][1]. Its label carries a boxed warning about infections and lymphoma and other cancers from a lowered immune system, and about harm in liver and lung transplant patients, where its use is not recommended[1][2].
  • Drugs@FDA still lists Rapamune as a prescription product, but on November 21, 2026 the FDA's NDC Directory and DailyMed listed no Rapamune-branded package; the same tablets and oral solution are sold as an authorized generic by Mylan (Viatris) under Rapamune's FDA applications, alongside other generic sirolimus[16][2][3].
Follow Rapamune by email

We'll email you when Rapamune's FDA label changes, when the FDA acts on it, and when new trials for Lymphangioleiomyomatosis open. Unsubscribe anytime.

You'll get, for Lymphangioleiomyomatosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Sirolimus fits

Rapamune (sirolimus) is a once-daily mTOR inhibitor that the FDA approved for lymphangioleiomyomatosis (LAM) on May 28, 2015, and Pfizer called it the first approved treatment that helps stabilize lung function in LAM[4][7].

  • The 2016 American Thoracic Society and Japanese Respiratory Society guideline on LAM makes recommendations for sirolimus treatment and against doxycycline and hormonal therapy[13].
  • Generic sirolimus tablets and oral solution from the makers Drugs@FDA lists carry the same LAM indication on their current labels[17][16].
  • Trial Friend's LAM page lists no other FDA-approved drug, and Afinitor (everolimus), another mTOR inhibitor, is approved for kidney angiomyolipoma with tuberous sclerosis complex but has no LAM indication on its label[15].
  • Hyftor (sirolimus) gel from Nobelpharma is a separate product, approved on March 22, 2022 for facial angiofibroma with tuberous sclerosis in people 6 and older, and its label does not cover LAM[14][17].
  • Fyarro, a sirolimus given by IV, is also a separate product, approved for malignant PEComa rather than LAM[17].
  • A ClinicalTrials.gov search on November 19, 2026 found no Phase 3 trial comparing sirolimus with another drug in LAM, since MILES compared it with placebo[12][10].
  • In MILES, lung function decline resumed after sirolimus was stopped, a finding the label reports in its trial section[1].
  • Anyone weighing Rapamune or generic sirolimus can ask a LAM specialist how lung function tests and sirolimus blood levels would guide their treatment, and how the label's contraception and vaccine rules fit their plans.

How Sirolimus works

In LAM, abnormal muscle-like cells called LAM cells grow in the lungs, lymph nodes and kidneys. The label explains that these cells carry changes that switch off the tuberous sclerosis complex (TSC) genes, and losing those genes turns on a growth signal called mTOR, which makes the cells multiply and release growth factors for lymph vessels[1].

Sirolimus binds a protein inside cells called FKBP-12, and that pair blocks mTOR, which slows the growth of LAM cells[1]. In the main LAM trial, blood levels of VEGF-D, a lymph vessel growth factor that runs high in LAM, fell on sirolimus and stayed about level on placebo[1]. Sirolimus also calms T cells, the immune cells that attack a transplanted kidney, which is why the same drug is used to prevent rejection and why it raises the risk of infection[1]. The label notes that the immune effect has lasted up to 6 months after stopping in some animal studies[1].

Side effects and safety

What patients report
Boxed warning
A lowered immune system on Rapamune can raise the risk of infection and of lymphoma and other cancers. For kidney transplant use, the label says only doctors experienced in immune-suppressing treatment and transplant care should prescribe it. Rapamune is not recommended in liver or lung transplant patients: in liver transplant studies it was linked to more deaths, lost grafts and clots in the liver's main artery (hepatic artery thrombosis), and in lung transplant patients the airway join made during surgery has broken down, most often fatally.
Label warnings
  • Infection, lymphoma and skin cancer. includes tuberculosis, fatal infections and sepsis; in the kidney transplant studies lymphoma or related disease occurred in 0.7-3.2% on Rapamune against 0.6-0.8% on the comparison drugs; the label asks people to limit sun and UV exposure with protective clothing and high-factor sunscreen
  • Allergic reactions and angioedema. anaphylaxis, swelling under the skin (angioedema), peeling skin and inflamed blood vessels; angioedema is more likely with ACE inhibitor blood pressure drugs or high sirolimus levels
  • Fluid buildup and slow wound healing. swollen legs, lymphedema, fluid around the lungs, belly or heart, including fluid around the heart that needed draining; wounds can heal slowly or reopen
  • Interstitial lung disease. lung inflammation with no infection found, some fatal, sometimes with high blood pressure in the lungs; the risk may rise with higher sirolimus levels, and some cases cleared when the dose was cut or the drug stopped
  • High cholesterol and triglycerides. in the transplant studies high cholesterol occurred in 43-46% and high triglycerides in 45-57% on Rapamune, against 23% each on placebo; lipids are watched throughout
  • Kidney effects and protein in the urine. kidney function can fall when Rapamune is combined with cyclosporine; the label recommends periodic urine protein tests
  • Reactivated viruses. BK virus kidney disease and progressive multifocal leukoencephalopathy (PML), a brain infection that has been fatal
  • Clotting disorders with calcineurin inhibitors. combining Rapamune with cyclosporine or tacrolimus may raise the risk of HUS, TTP and thrombotic microangiopathy, conditions in which small clots damage the kidneys and blood cells
  • Pregnancy and fertility. can harm an unborn baby; highly effective contraception before, during and for 12 weeks after treatment; low or absent sperm counts in men; ovarian cysts and period changes have been reported
  • Vaccines. live vaccines such as measles, mumps, rubella, varicella, yellow fever and oral typhoid are avoided, and other vaccines may work less well
  • Drug interactions. strong CYP3A4 and P-gp blockers or boosters are avoided, grapefruit juice is not used, and sirolimus levels are watched closely with cannabidiol
Most common in trials
Mouth sores (stomatitis)DiarrheaAbdominal painNauseaSore nose and throat (nasopharyngitis)AcneChest painSwelling in the legsUpper respiratory infectionsHeadacheDizzinessMuscle achesHigh cholesterolWeight loss
What gets monitored
  • A sirolimus blood trough level 10 to 20 days after starting, with the dose adjusted to keep it between 5 and 15ng/mL in LAM
  • At least 7 to 14 days on a new dose before the next adjustment
  • Trough levels at least every 3 months once the dose is stable
  • Levels measured with the same lab method, since chromatography and immunoassay results are not interchangeable
  • Cholesterol and triglycerides during treatment
  • Periodic urine protein tests
Report a suspected reaction to Pfizer at 1-800-438-1985, Viatris (Greenstone on the tablet label) at 1-877-446-3679 for the authorized generic, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

Rapamune carries a boxed warning: a lowered immune system can raise the risk of infection and of lymphoma and other cancers, and the drug is not recommended in liver or lung transplant patients, where it was linked to more deaths, lost grafts and hepatic artery clots after liver transplant and to breakdown of the airway join after lung transplant[1].

In the LAM trial, which treated 46 of its 89 patients with Rapamune, side effects in at least 20% on Rapamune and more common than on placebo were mouth sores (stomatitis), diarrhea, abdominal pain, nausea, sore nose and throat, acne, chest pain, swelling in the legs, upper respiratory infections, headache, dizziness, muscle aches and high cholesterol[1].

Weight loss was also reported more often than on placebo, and 11% of LAM patients stopped because of side effects, with no single side effect causing more than 1 person to stop[1]. The label does not give a rate for each of these in LAM. The MILES paper reports that side effects were more common on sirolimus, while serious side effects did not differ significantly between the groups[9].

Other label warnings cover allergic reactions and angioedema, fluid buildup around the lungs, belly or heart, slow wound healing, interstitial lung disease, high cholesterol and triglycerides, kidney decline and urine protein, reactivated BK virus and PML, harm to an unborn baby, low sperm counts and skin cancer[1].

In kidney transplant patients, the most common side effects (30% or more) were swelling in the legs, high triglycerides, high blood pressure, high cholesterol, raised creatinine, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, joint pain, pain and low platelets[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Sirolimus

For LAM, the starting dose is 2mg once a day by mouth, taken the same way each day, either always with food or always without[1]. A blood test for the sirolimus trough level, the lowest level just before a dose, is done 10 to 20 days after starting, and the dose is adjusted to keep it between 5 and 15ng/mL[1]. Because sirolimus leaves the body slowly, the label says to stay on a new dose for at least 7 to 14 days before changing it again, and to check levels at least every 3 months once the dose is stable[1].

Tablets are not crushed, chewed or split; people who cannot swallow them are prescribed the oral solution, which is mixed into at least 2 ounces of water or orange juice in a glass or plastic cup, drunk at once, and followed by at least 4 more ounces of water or orange juice[1]. Grapefruit juice must not be used or drunk with it[1]. The maintenance dose is cut by about a third with mild or moderate liver impairment and by about half with severe liver impairment; no change is needed for kidney impairment[1].

The label says to avoid strong CYP3A4 and P-gp blockers such as ketoconazole, voriconazole, itraconazole, erythromycin and clarithromycin, and strong boosters such as rifampin and rifabutin, and to watch levels closely with cannabidiol[1]. Sirolimus made under Rapamune's applications comes as 0.5mg, 1mg and 2mg tablets and as a 1mg/mL oral solution in a 60mL bottle that is kept in the refrigerator[1][3].

In kidney transplant use the dosing is different: a loading dose on day 1, then a daily dose taken 4 hours after cyclosporine, with cyclosporine withdrawn after 2 to 4 months in lower-risk patients[1].

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Why it costs what it costs

A daily pill or oral solution taken long term. The label gives no price. Drugs@FDA lists generic sirolimus tablets from Dr. Reddy's, Zydus, Glenmark and Alkem and generic oral solution from Novitium, Apotex, Amneal, Hetero, MSN and Rising as marketed prescription products, and their current labels include LAM[16][17]. No Rapamune copay card was found on Pfizer's pages[18].

Access and eligibility

Manufacturer
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Pfizer RxPathways

Pfizer's general access program, which includes the Pfizer Patient Assistance Program. Rapamune did not appear on the RxPathways Available Medications page when it was read on November 19, 2026, and the page says to call 1-844-989-PATH (7284) about a medicine that is not listed. No Rapamune copay card or eligibility terms were found on Pfizer's own pages. Generic sirolimus makers do not publish a patient program.

Visit Pfizer RxPathways
Eligibility requirement

The LAM indication covers patients with lymphangioleiomyomatosis and sets no age, lung function or TSC limit, while safety and efficacy in people under 18 with LAM have not been established[1]. The MILES trial enrolled people with moderate lung impairment[9]. The kidney transplant indication covers people 13 and older, and safety and efficacy have not been established in children under 13 or in high-risk transplant patients under 18[1]. Rapamune is contraindicated in people allergic to it, and the label does not recommend it after a liver or lung transplant[1]. Women who could become pregnant are advised to use highly effective contraception from before the first dose until 12 weeks after the last[1].

Source: Pfizer RxPathways Available Medications

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

The FDA approved the LAM use on the MILES trial (NCT00414648), a Phase 3 study led by the University of Cincinnati within the NIH Rare Lung Diseases Consortium[10][7]. Pfizer said it supplied the study drug and part of the funding and had no role in the design or conduct of the study[7]. MILES randomized 89 people with LAM and moderate lung impairment to sirolimus, adjusted to a blood level of 5 to 15ng/mL, or placebo for 12 months, then followed them off treatment for another 12 months[1][9].

During treatment, FEV1, the amount of air blown out in 1 second, fell by 12mL a month on placebo and rose by 1mL a month on sirolimus, a difference of 13mL a month[1]. Over the 12 months the gap was 153mL, about 11% of the average FEV1 at the start, and forced vital capacity improved in the same way[1]. The paper also reports better quality of life and functional performance, while 6-minute walk distance and the lung's gas transfer (DLCO) did not differ significantly[9].

After sirolimus was stopped, lung function decline resumed and paralleled the placebo group[1][9]. The University of Cincinnati's MILED trial (NCT03150914) is testing early, long-term low-dose sirolimus to see whether it prevents progression; ClinicalTrials.gov, last updated December 2024, lists it as active and not recruiting, with no results posted[11].

Development history

Rapamune oral solution was first approved on September 15, 1999 under NDA 021083, and the tablets followed on August 25, 2000 under NDA 021110, both to prevent rejection after a kidney transplant[5][6]. Pfizer announced on February 20, 2015 that the FDA had accepted its application to add LAM for priority review[8]. The FDA approved the LAM use on May 28, 2015, and the approval letter notes that the drug has an orphan drug designation for this use[4].

Pfizer called Rapamune the first approved treatment that helps stabilize lung function in LAM[7]. A 5mg tablet is listed as discontinued, and Drugs@FDA notes a Federal Register finding that it was not withdrawn for safety or effectiveness reasons[6]. The current label names Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., and was revised in October 2024[1].

Ask anything about Sirolimus
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Lymphangioleiomyomatosis trials

Common questions about Sirolimus

▸What is Sirolimus (Rapamune)?

A once-daily pill or oral solution, taken by mouth, that is FDA approved for lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women[13]. The FDA approved the LAM use on May 28, 2015[4]. Rapamune was first approved in 1999 to help prevent rejection after a kidney transplant, and that is still its other labeled use, for people 13 and older[5][1]. Its label carries a boxed warning about infections and lymphoma and other cancers from a lowered immune system, and about harm in liver and lung transplant patients, where its use is not recommended[1][2]. Drugs@FDA still lists Rapamune as a prescription product, but on November 21, 2026 the FDA's NDC Directory and DailyMed listed no Rapamune-branded package; the same tablets and oral solution are sold as an authorized generic by Mylan (Viatris) under Rapamune's FDA applications, alongside other generic sirolimus[16][2][3].

▸How does Sirolimus work?

In LAM, abnormal muscle-like cells called LAM cells grow in the lungs, lymph nodes and kidneys. The label explains that these cells carry changes that switch off the tuberous sclerosis complex (TSC) genes, and losing those genes turns on a growth signal called mTOR, which makes the cells multiply and release growth factors for lymph vessels[1]. Sirolimus binds a protein inside cells called FKBP-12, and that pair blocks mTOR, which slows the growth of LAM cells[1]. In the main LAM trial, blood levels of VEGF-D, a lymph vessel growth factor that runs high in LAM, fell on sirolimus and stayed about level on placebo[1]. Sirolimus also calms T cells, the immune cells that attack a transplanted kidney, which is why the same drug is used to prevent rejection and why it raises the risk of infection[1]. The label notes that the immune effect has lasted up to 6 months after stopping in some animal studies[1].

▸What are the side effects of Sirolimus?

Rapamune carries a boxed warning: a lowered immune system can raise the risk of infection and of lymphoma and other cancers, and the drug is not recommended in liver or lung transplant patients, where it was linked to more deaths, lost grafts and hepatic artery clots after liver transplant and to breakdown of the airway join after lung transplant[1]. In the LAM trial, which treated 46 of its 89 patients with Rapamune, side effects in at least 20% on Rapamune and more common than on placebo were mouth sores (stomatitis), diarrhea, abdominal pain, nausea, sore nose and throat, acne, chest pain, swelling in the legs, upper respiratory infections, headache, dizziness, muscle aches and high cholesterol[1]. Weight loss was also reported more often than on placebo, and 11% of LAM patients stopped because of side effects, with no single side effect causing more than 1 person to stop[1]. The label does not give a rate for each of these in LAM. The MILES paper reports that side effects were more common on sirolimus, while serious side effects did not differ significantly between the groups[9]. Other label warnings cover allergic reactions and angioedema, fluid buildup around the lungs, belly or heart, slow wound healing, interstitial lung disease, high cholesterol and triglycerides, kidney decline and urine protein, reactivated BK virus and PML, harm to an unborn baby, low sperm counts and skin cancer[1]. In kidney transplant patients, the most common side effects (30% or more) were swelling in the legs, high triglycerides, high blood pressure, high cholesterol, raised creatinine, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, joint pain, pain and low platelets[1].

▸How is Sirolimus taken?

For LAM, the starting dose is 2mg once a day by mouth, taken the same way each day, either always with food or always without[1]. A blood test for the sirolimus trough level, the lowest level just before a dose, is done 10 to 20 days after starting, and the dose is adjusted to keep it between 5 and 15ng/mL[1]. Because sirolimus leaves the body slowly, the label says to stay on a new dose for at least 7 to 14 days before changing it again, and to check levels at least every 3 months once the dose is stable[1]. Tablets are not crushed, chewed or split; people who cannot swallow them are prescribed the oral solution, which is mixed into at least 2 ounces of water or orange juice in a glass or plastic cup, drunk at once, and followed by at least 4 more ounces of water or orange juice[1]. Grapefruit juice must not be used or drunk with it[1]. The maintenance dose is cut by about a third with mild or moderate liver impairment and by about half with severe liver impairment; no change is needed for kidney impairment[1]. The label says to avoid strong CYP3A4 and P-gp blockers such as ketoconazole, voriconazole, itraconazole, erythromycin and clarithromycin, and strong boosters such as rifampin and rifabutin, and to watch levels closely with cannabidiol[1]. Sirolimus made under Rapamune's applications comes as 0.5mg, 1mg and 2mg tablets and as a 1mg/mL oral solution in a 60mL bottle that is kept in the refrigerator[1][3]. In kidney transplant use the dosing is different: a loading dose on day 1, then a daily dose taken 4 hours after cyclosporine, with cyclosporine withdrawn after 2 to 4 months in lower-risk patients[1].

▸Is Sirolimus FDA approved?

Yes. The FDA approved Rapamune (sirolimus) for patients with lymphangioleiomyomatosis (LAM) on May 28, 2015.

Who: the label names patients with LAM and sets no lung function or TSC limit; safety and efficacy under age 18 have not been established.

Evidence: the MILES trial, where lung function held steady on sirolimus and fell on placebo over 12 months.

Generics: generic sirolimus tablets and oral solution carry the same LAM indication.

Other use: Rapamune is also approved to prevent rejection after a kidney transplant in people 13 and older.

Source: Rapamune prescribing information

▸What is the Rapamune dose for LAM?

The label's starting dose for LAM is 2mg once a day by mouth, then adjusted to a blood trough level of 5 to 15ng/mL[1].

First level: 10 to 20 days after starting.

Between changes: at least 7 to 14 days on a new dose.

Once stable: levels at least every 3 months.

Liver impairment: the maintenance dose is cut by about a third (mild or moderate) or half (severe).

With food: taken the same way every day, always with food or always without.

Source: Rapamune prescribing information

▸What are the side effects of sirolimus for LAM?

In the LAM trial, side effects in at least 20% on Rapamune and more common than placebo included mouth sores, diarrhea, abdominal pain, nausea, acne, chest pain, leg swelling, headache, dizziness, muscle aches and high cholesterol[1].

Also: sore nose and throat, upper respiratory infections and weight loss.

Stopped treatment: 11% of LAM patients, because of side effects.

Boxed warning: infection, lymphoma and other cancers, plus harm in liver and lung transplant patients.

Lung warning: interstitial lung disease, some fatal, can occur.

Source: Rapamune prescribing information

▸How well did sirolimus work in the MILES trial?

Over 12 months, FEV1 fell by 12mL a month on placebo and rose by 1mL a month on sirolimus, a gap of 153mL or about 11% of the starting average[1].

Trial size: 89 people with LAM and moderate lung impairment, 46 on sirolimus.

Other results: forced vital capacity improved, and the paper reports better quality of life.

No difference: 6-minute walk distance and DLCO.

After stopping: lung function decline resumed and paralleled placebo.

Source: McCormack et al., NEJM 2011

▸Is there a generic Rapamune for LAM?

Yes. Drugs@FDA lists generic sirolimus tablets and oral solution from several makers as marketed, and their current labels include LAM[16][17].

Tablets: Dr. Reddy's, Zydus, Glenmark and Alkem, rated AB to Rapamune tablets.

Oral solution: Novitium, Apotex, Amneal, Hetero, MSN and Rising, rated AA to Rapamune solution.

Authorized generic: Mylan (Viatris) sells sirolimus tablets and oral solution made under Rapamune's own FDA applications, NDA 021110 and 021083, with the same label[2][3].

Blood levels: the label recommends a trough level check whenever the dosage form changes.

Source: Drugs@FDA sirolimus applications via openFDA

▸Is Hyftor the same as Rapamune?

No. Hyftor is a sirolimus gel rubbed on the face, approved on March 22, 2022 for facial angiofibroma with tuberous sclerosis, and its label does not cover LAM[14][17].

Rapamune: a pill or oral solution approved for LAM and kidney transplant.

Fyarro: a sirolimus given by IV for malignant PEComa.

Same molecule: Hyftor, Rapamune and Fyarro all contain sirolimus, but each has its own label, dose and uses.

Source: Drugs@FDA, Hyftor NDA 213478

▸Can you get pregnant while taking sirolimus for LAM?

The label says Rapamune can harm an unborn baby and that women should not be pregnant or become pregnant while taking it[1].

Contraception: highly effective contraception before the first dose, during treatment and for 12 weeks after the last dose.

Breastfeeding: whether sirolimus passes into human milk is not known; the label warns of possible serious effects in a breastfed baby and asks that the benefits of breastfeeding be weighed against the mother's need for sirolimus and any risk to the child.

Fertility: ovarian cysts and period changes in women and low sperm counts in men have been reported.

Source: Rapamune prescribing information

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. · 2024-10. RAPAMUNE (sirolimus) oral solution / tablets, for oral use. https://labeling.pfizer.com/showlabeling.aspx?id=139
  2. Mylan Pharmaceuticals Inc. via DailyMed · 2026-03-26. SIROLIMUS tablets, for oral use. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5908cd1a-fc5a-462f-99ed-1d8983e253c9
  3. Mylan Pharmaceuticals Inc. via DailyMed · 2026-10-16. SIROLIMUS oral solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=384cb547-55a4-47fc-a0a6-054c18a51b84
  4. U.S. Food and Drug Administration · 2015-05-28. Rapamune (sirolimus) Oral Solution, 1 mg/mL, Rapamune (sirolimus) Tablets, 0.5 mg, 1 mg, and 2 mg, Approval Letter, NDA 021083/S-055 and NDA 021110/S-073. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021083Orig1s055,021110Orig1s073ltr.pdf
  5. U.S. Food and Drug Administration · 1999-09-15. RAPAMUNE oral solution, NDA 021083. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021083
  6. U.S. Food and Drug Administration · 2000-08-25. RAPAMUNE tablets, NDA 021110. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021110
  7. Pfizer · 2015-05-29. Pfizer's RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_rapamune_sirolimus_becomes_first_fda_approved_treatment_for_lymphangioleiomyomatosis_lam_a_rare_progressive_lung_disease
  8. Pfizer · 2015-02-20. FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM). https://www.pfizer.com/news/press-release/press-release-detail/fda_accepts_supplemental_new_drug_application_for_priority_review_of_rapamune_sirolimus_for_treatment_of_lymphangioleiomyomatosis_lam
  9. New England Journal of Medicine (PubMed 21410393) · 2011-04-28. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. https://pubmed.ncbi.nlm.nih.gov/21410393/
  10. ClinicalTrials.gov. Efficacy and Safety of Sirolimus in LAM (MILES). https://clinicaltrials.gov/study/NCT00414648
  11. ClinicalTrials.gov. Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial (MILED). https://clinicaltrials.gov/study/NCT03150914
  12. American Journal of Respiratory and Critical Care Medicine (PubMed 27628078) · 2016-09-15. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. https://pubmed.ncbi.nlm.nih.gov/27628078/
  13. U.S. Food and Drug Administration · 2022-03-22. HYFTOR (sirolimus) topical gel 0.2%, NDA 213478. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213478
  14. Novartis Pharmaceuticals Corporation via DailyMed · 2026-06-01. AFINITOR- everolimus tablet / AFINITOR DISPERZ- everolimus tablet, for suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04
  15. U.S. Food and Drug Administration (openFDA) · 2026-11-19. Drugs@FDA applications with sirolimus as the active ingredient. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:SIROLIMUS&limit=100
  16. U.S. Food and Drug Administration (openFDA) · 2026-11-19. FDA drug labels with sirolimus as the generic name. https://api.fda.gov/drug/label.json?search=openfda.generic_name:sirolimus&limit=50
  17. Pfizer · 2026-11-19. Available Medications | Pfizer RxPathways. https://www.pfizerrxpathways.com/available-medications

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Rapamune by email

We'll email you when Rapamune's FDA label changes, when the FDA acts on it, and when new trials for Lymphangioleiomyomatosis open. Unsubscribe anytime.

You'll get, for Lymphangioleiomyomatosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site